On behalf of Ulf-Henrik Mellqvist, MD, PhD, meeting chairman, we are pleased to invite you to the Nordic Expert Practice^SM in Multiple Myeloma meeting in Stockholm, on 7 February 2012.

During this meeting, leaders in the field will discuss, in an interactive format, clinical issues encountered daily by practicing physicians, focusing on multiple myeloma.

Radisson Blu Arlandia Hotel

Kabinvägen 3

190 60 Stockholm-Arlanda

Sweden

This educational activity is designed for hematologists, oncologists, and other healthcare providers from the Nordic Region (Denmark, Finland, Norway, Sweden, and Iceland) involved and/or interested in the management of patients with multiple myeloma.

After successful completion of this educational activity, participants should be able to:

• Discuss developments in multiple myeloma from the 2011 American Society of Hematology (ASH) Annual Meeting and translate these developments into daily clinical practice
• Assess currently available and emerging treatment options for multiple myeloma
• Describe the importance of bone health in multiple myeloma
• Evaluate the use of prognostic markers to guide the therapeutic decision-making process in patients with chronic lymphocytic leukemia

Chairman:

Ulf-Henrik Mellqvist, MD, PhD
Sahlgrenska University Hospital
Gothenburg, Sweden

Nordic Faculty Members:

Pekka Anttila, MD

Helsinki University Central Hospital
Helsinki, Finland

Gösta Gahrton, MD
Karolinska Institute
Stockholm, Sweden

Torben Plesner, MD
University of Southern Denmark
Odense, Denmark

Anders Waage, MD
University Hospital Trondheim
Trondheim, Norway

Guest Faculty Members:

Emili Montserrat, MD
Institute of Hematology and Oncology
Barcelona, Spain

Antonio Palumbo, MD
University of Torino
Torino, Italy

Evangelos Terpos, MD, PhD
University of Athens
Athens, Greece

Monday, 6 February 2012

20.00 – 22.00

Welcome reception and dinner

Tuesday, 7 February 2012

Part I: Educational Session
09.10 – 09.35	Educational Session The role of bone targeted therapy in myeloma Evangelos Terpos, MD, PhD
09.35 – 10.00	Educational Session Chronic lymphocytic leukemia: Advances in treatment Emili Montserrat, MD
10.00 – 10.30	Coffee break
Part II: Updates from the 2011 ASH Annual Meeting
10.30 – 10.55	Myeloma treatment: Eligible for transplant  Torben Plesner, MD
10.55 – 11.20	Myeloma treatment: Non-eligible for transplant Anders Waage, MD
11.20 – 11.45	Relapsed multiple myeloma Pekka Anttila, MD
11.45 – 12.15	Myeloma: Maintenance therapy Ulf-Henrik Mellqvist, MD
12.15 – 13.15	Lunch
Part III: Interactive Discussions
13.15 – 14.15	Interactive Debate Should "cure" or "control" be the aim of initial therapy for newly diagnosed multiple myeloma?
	13.15 – 13.35 "Cure" position: Torben Plesner, MD
	13.35 – 13.55 "Control" position: Anders Waage, MD
	13.55 – 14.15 Commentary: Antonio Palumbo, MD
14.15 – 15.55	Interactive Case-Based Discussions Case #1: Overcoming adverse risk factors in the high-risk "young" patient with myeloma Case #1: Antonio Palumbo, MD
	Case #2: Maintenance therapy post autologous stem cell transplantation Case #2: Ulf-Henrik Mellqvist, MD, PhD
	Case #3: Relapsed multiple myeloma  Case #3: Pekka Anttila, MD
15.55 – 16.00	Summary and concluding remarks Ulf-Henrik Mellqvist, MD, PhD